# Elements of Comprehensive Participant Readiness and Resilience Framework – A journey approach to HIV cure research

Creating a framework that supports study participants throughout their experience—and beyond

#### **Before ATIs**

**Reframe** the approach to informed consent to a person-centered framework (e.g., decision support around ATI trial participation, availability of peer navigators for decision support).

**Enhance** the informed consent process (e.g., multi-media/multi-modal informed consent process to accommodate disparate learning styles, literacy levels and cultural, linguistic and socieconomic backgrounds of prospective participants).

**Provide** clear information about known and potential risks of ATIs (based on previous trials), risks of experimental interventions and risks of monitoring procedures.

**Explain** to prospective participants the legal liabilities that may result from not disclosing their HIV status to sex partners during an ATI.

**Discuss** the potential long-term adverse events that can result from an ATI.

**Ensure** that treatment costs for adverse events due to the ATI are not borne by the participant.

**Conduct** pre-ATI assessments to determine a prospective participant's understanding and psychosocial readiness.

**Plan** and provide support around partner protection measures (for HIV-serodifferent relationships).

**Multi-center trials** must have a single lead institutional review board; there should be only one informed consent for the participant to sign.

### **During ATIs**

**Conduct** close monitoring without overburdening trial participants.

**Build** support around partner protection measures.

**Understand** and consider the relationship dynamics and potential risks, including the risk for intimate partner violence.

**Conduct** psychosocial and mental health assessments and support—particularly addressing anxiety around being off HIV treatment.

**Assess** the impact of ATI participation on other people in participants' immediate social circles.

**Develop** and provide home-based viral load testing to self-assess transmissibility potential.

In case of unexpected intercurrent events (e.g., COVID-19, mpox pandemics), establish a mechanism for consultation with ATI participants, participant-centered communications, mental health safety screening and guidance to reduce risks to trial participants.

## After ATIs

**Conduct** a mental health follow-up after the ATI period and study have ended.

**Establish** regular check-ins with participants following an ATI or the study's completion every six months.

**Monitor** for potential long-term effects of ATIs.

**Provide** ART resistance testing and assistance with ART regimen change if needed.

**Disseminate** research outcomes to participants in a way that is accessible to them.

**Provide** medical journals and other publications in which the study's findings appear free of charge to study participants.

**Continue** to check in with participants who have resumed ART after an ATI period has ended.

**For participants** who are post-intervention controllers, provide continued psychosocial support around being off ART and provide partner protection support.

**For participants** who are cured, provide psychosocial support around the anxiety of potentially having to relive the experience of an HIV diagnosis if they are no longer cured; offer support systems to maintain the social benefits they had received during the time they were living with HIV (e.g., housing benefits) and offer guidance around PrEP uptake if needed.

#### ATI support program goals

**Provide** high-quality research and patient/participant involvement in ATI trial designs.

**Study** designs should take into account other circulating endemic viruses such as new COVID-19 variants and/or seasonal flu, and how they may impact HIV viral load during an ATI.

**Establish** mechanisms to better understand research attitudes and perceptions around ATI trials.

**Develop** greater support services for ATI trial participants and partners mental health services, access to pre-exposure prophylaxis (PrEP), referral to a support hotline. **Create** an ATI participant experience database and research hub.

**Offer** professional development opportunities for community advisory board (CAB) members or former trial participants (e.g., certified peer navigators).

**View** behavioral and social sciences research as a gateway to ATI research participation.

**Examine** how the arts can be used to inform, engage and build trust among members of community groups underrepresented in HIV cure research (with approaches to measure effectiveness of community engagement). **Create** and expand programs that encourage support of and participation in HIV cure research (e.g., HIV cure research ambassadors).

**Use** person-centered language—e.g., *participants* instead of *subjects*.

**Develop** community-centered education materials around ATI trials.

**Provide** adequate compensation to trial participants and CAB members for their participation expenses.

It is essential to involve primary care physicians during the entire research participation; this includes referrals to independent counselling and other support mechanisms during and after ATI periods.